SG11202103972SA - Neurological disease treatment with zilucoplan - Google Patents
Neurological disease treatment with zilucoplanInfo
- Publication number
- SG11202103972SA SG11202103972SA SG11202103972SA SG11202103972SA SG11202103972SA SG 11202103972S A SG11202103972S A SG 11202103972SA SG 11202103972S A SG11202103972S A SG 11202103972SA SG 11202103972S A SG11202103972S A SG 11202103972SA SG 11202103972S A SG11202103972S A SG 11202103972SA
- Authority
- SG
- Singapore
- Prior art keywords
- zilucoplan
- neurological disease
- disease treatment
- neurological
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/322—Retractable needles, i.e. disconnected from and withdrawn into the syringe barrel by the piston
- A61M5/3234—Fully automatic needle retraction, i.e. in which triggering of the needle does not require a deliberate action by the user
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Environmental & Geological Engineering (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862748659P | 2018-10-22 | 2018-10-22 | |
US201862777524P | 2018-12-10 | 2018-12-10 | |
US201962815575P | 2019-03-08 | 2019-03-08 | |
US201962837974P | 2019-04-24 | 2019-04-24 | |
US201962844388P | 2019-05-07 | 2019-05-07 | |
US201962899864P | 2019-09-13 | 2019-09-13 | |
PCT/US2019/057316 WO2020086506A1 (en) | 2018-10-22 | 2019-10-22 | Neurological disease treatment with zilucoplan |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202103972SA true SG11202103972SA (en) | 2021-05-28 |
Family
ID=68696508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202103972SA SG11202103972SA (en) | 2018-10-22 | 2019-10-22 | Neurological disease treatment with zilucoplan |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220133841A1 (en) |
EP (1) | EP3870221A1 (en) |
JP (1) | JP2022508952A (en) |
KR (1) | KR20210080390A (en) |
CN (1) | CN113226368A (en) |
AU (1) | AU2019365804A1 (en) |
BR (1) | BR112021007083A2 (en) |
CA (1) | CA3115828A1 (en) |
MA (1) | MA53986A (en) |
MX (1) | MX2021004366A (en) |
SG (1) | SG11202103972SA (en) |
TW (1) | TW202034943A (en) |
WO (1) | WO2020086506A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019011053A2 (en) | 2016-12-07 | 2019-10-15 | Ra Pharmaceuticals Inc | complement activity modulators |
BR112022002522A2 (en) | 2019-09-12 | 2022-08-16 | Ra Pharmaceuticals Inc | TREATMENT OF NEUROLOGICAL DISEASES WITH COMPLEMENT INHIBITORS |
WO2023215586A1 (en) | 2022-05-05 | 2023-11-09 | UCB Biopharma SRL | Treatment of myasthenia gravis with zilucoplan |
WO2023215587A1 (en) | 2022-05-05 | 2023-11-09 | UCB Biopharma SRL | Treatment of myasthenia gravis with zilucoplan |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007293013B2 (en) * | 2006-09-05 | 2013-06-27 | Alexion Pharmaceuticals, Inc. | Method and compositions for the treatment of antibody mediated neuropathies |
WO2010025510A1 (en) | 2008-09-03 | 2010-03-11 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
EP3628680B1 (en) * | 2014-06-12 | 2021-09-08 | RA Pharmaceuticals, Inc. | Modulation of complement activity |
RS62630B9 (en) | 2015-01-28 | 2022-04-29 | Ra Pharmaceuticals Inc | Modulators of complement activity |
-
2019
- 2019-10-22 JP JP2021547053A patent/JP2022508952A/en active Pending
- 2019-10-22 EP EP19809662.0A patent/EP3870221A1/en active Pending
- 2019-10-22 AU AU2019365804A patent/AU2019365804A1/en active Pending
- 2019-10-22 KR KR1020217012043A patent/KR20210080390A/en active Search and Examination
- 2019-10-22 WO PCT/US2019/057316 patent/WO2020086506A1/en active Application Filing
- 2019-10-22 MX MX2021004366A patent/MX2021004366A/en unknown
- 2019-10-22 SG SG11202103972SA patent/SG11202103972SA/en unknown
- 2019-10-22 TW TW108138005A patent/TW202034943A/en unknown
- 2019-10-22 CA CA3115828A patent/CA3115828A1/en active Pending
- 2019-10-22 CN CN201980084982.8A patent/CN113226368A/en active Pending
- 2019-10-22 MA MA053986A patent/MA53986A/en unknown
- 2019-10-22 BR BR112021007083-4A patent/BR112021007083A2/en unknown
- 2019-10-22 US US17/287,581 patent/US20220133841A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220133841A1 (en) | 2022-05-05 |
EP3870221A1 (en) | 2021-09-01 |
CN113226368A (en) | 2021-08-06 |
TW202034943A (en) | 2020-10-01 |
BR112021007083A2 (en) | 2021-08-03 |
WO2020086506A1 (en) | 2020-04-30 |
KR20210080390A (en) | 2021-06-30 |
MX2021004366A (en) | 2021-08-16 |
CA3115828A1 (en) | 2020-04-30 |
JP2022508952A (en) | 2022-01-19 |
AU2019365804A1 (en) | 2021-05-20 |
MA53986A (en) | 2022-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202103972SA (en) | Neurological disease treatment with zilucoplan | |
IL263188B (en) | Treatment for parkinson's disease | |
GB201813876D0 (en) | Treatment | |
IL267818A (en) | Methods for the treatment of neurological disorders | |
IL255506A (en) | Method for the treatment of neurological disease | |
GB201721287D0 (en) | Treatment for inflammatory disease | |
GB201620611D0 (en) | Treatment of neurological diseases | |
IL281792A (en) | Treatment methods | |
GB201800546D0 (en) | Treatment | |
IL281839A (en) | Treatment methods | |
IL271322A (en) | Non-invasive neural interface | |
IL282361A (en) | Treatment of neurological diseases | |
IL270788A (en) | Sulfonylurea compounds in the treatment of disease associated with uv-induced damage | |
GB201914296D0 (en) | Treatment | |
GB201715763D0 (en) | Treatment of neurological disease | |
GB201811629D0 (en) | Venous disease | |
SG11202101196TA (en) | Behavioural treatment | |
GB201814905D0 (en) | Treatment | |
GB201811911D0 (en) | Treatment of disease | |
GB201811912D0 (en) | Treatment of disease | |
GB201810974D0 (en) | Treatment of disease | |
GB201913294D0 (en) | Neurological modification therapy | |
ZA201807944B (en) | Treatment for parkinson's disease | |
GB201912760D0 (en) | Treatment | |
GB201912365D0 (en) | Treatment |